UMB Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-494
Closed -$16.5K – 2342
2026
Q2
$16.5K Sell
494
-289
-37% -$7.18K ﹤0.01% 1747
2026
Q1
$16.4K Buy
783
+272
+53% +$6.12K ﹤0.01% 1671
2025
Q4
$11.8K Sell
511
-12
-2% -$395 ﹤0.01% 1759
2025
Q3
$15.7K Sell
523
-104
-17% -$3.12K ﹤0.01% 1524
2025
Q2
$22.8K Buy
627
+100
+19% +$3.6K ﹤0.01% 1340
2025
Q1
$19.1K Sell
527
-273
-34% -$11.4K ﹤0.01% 1340
2024
Q4
$33.7K Sell
800
-233
-23% -$11.6K ﹤0.01% 1067
2024
Q3
$57.4K Buy
1,033
+75
+8% +$3.82K ﹤0.01% 830
2024
Q2
$39.4K Buy
958
+352
+58% +$15K ﹤0.01% 877
2024
Q1
$28.3K Hold
606
– – ﹤0.01% 970
2023
Q4
$29K Buy
606
+329
+119% +$12.8K ﹤0.01% 953
2023
Q3
$9.9K Sell
277
-157
-36% -$6.22K ﹤0.01% 1296
2023
Q2
$20K Buy
+434
New +$20.1K ﹤0.01% 1096

Other funds holding RARE

UMB Bank's RARE Position: Q3 2026 in Review

UMB Bank sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2026, closing a stake of 494 shares — an estimated $16.5K sold.

UMB Bank first reported a position in RARE in Q2 2023 and held it in 13 quarters. The position peaked at $57.4K in Q3 2024. 266 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • UMB Bank reported no remaining Ultragenyx Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • UMB Bank sold 494 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $16.5K.
  • UMB Bank first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and held it in 13 quarters.
  • UMB Bank's Ultragenyx Pharmaceutical position peaked at $57.4K in Q3 2024.
  • 266 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on UMB Bank's 13F filing for Q3 2026, filed 6 Nov 2026.